Hikma Pharmaceuticals Plc (HIK) Receives GBX 1,188.38 Consensus Price Target from Analysts

Shares of Hikma Pharmaceuticals Plc (LON:HIK) have earned a consensus rating of “Hold” from the ten research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is GBX 1,188.38 ($15.38).

HIK has been the topic of a number of research analyst reports. Citigroup increased their price target on Hikma Pharmaceuticals from GBX 1,250 ($16.18) to GBX 1,475 ($19.09) and gave the stock a “buy” rating in a research report on Tuesday, May 1st. Peel Hunt restated a “hold” rating on shares of Hikma Pharmaceuticals in a research report on Friday, May 18th. Jefferies Financial Group restated a “hold” rating and set a GBX 997 ($12.91) price target on shares of Hikma Pharmaceuticals in a research report on Friday, May 18th. Numis Securities lowered Hikma Pharmaceuticals to an “add” rating and increased their price target for the stock from GBX 1,300 ($16.83) to GBX 1,560 ($20.19) in a research report on Friday, May 18th. Finally, Barclays restated an “underweight” rating on shares of Hikma Pharmaceuticals in a research report on Monday, May 21st.

Hikma Pharmaceuticals opened at GBX 1,683.50 ($21.79) on Tuesday, according to MarketBeat Ratings. Hikma Pharmaceuticals has a one year low of GBX 814.20 ($10.54) and a one year high of GBX 2,346 ($30.37).

In other news, insider Sigurdur Olafsson acquired 20,000 shares of the firm’s stock in a transaction on Wednesday, May 30th. The shares were purchased at an average cost of GBX 1,309 ($16.94) per share, for a total transaction of £261,800 ($338,899.68). Also, insider John J. Castellani acquired 1,000 shares of the firm’s stock in a transaction on Tuesday, May 22nd. The stock was purchased at an average price of GBX 1,377 ($17.83) per share, for a total transaction of £13,770 ($17,825.24).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Featured Story: Short Selling Stocks and Day Traders

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply